Full-Time

Executive Director Regulatory Affairs Lead

Global Regulatory Portfolio

Updated on 8/1/2026

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$284.7k - $364.7k/yr

+ Annual bonus plan + Discretionary equity awards + Employee Stock Purchase Plan

Remote in USA

Remote

Remote within the United States, with approximately 10–20% travel required.

Category
Legal & Compliance (1)
Required Skills
Microsoft Office
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to BeOne

See people who can refer or advise you

Requirements
  • A BA/BS degree with more than 14 years of experience in the biotechnical or pharmaceutical industry and at least 10 years of Regulatory experience, or an MA/MS/MBA with more than 10 years of overall and Regulatory experience.
  • A thorough understanding of the drug development process, the pharmaceutical industry, the healthcare environment, regulatory requirements, and policy trends.
  • Expertise in global strategy development and execution, including INDs, CTAs, NDAs, BLAs, MAAs, lifecycle management, Health Authority interactions, regulatory team leadership and management, and development and implementation of regulatory strategies.
  • Business acumen and the ability to make sound business decisions.
  • Strategic ability to identify and address major strategic challenges and opportunities, expedite development and regulatory processes, and balance short-term needs with long-term vision.
  • The ability to deliver goals within a cross-functional team or partnership environment.
  • Excellent interpersonal, oral, and written communication skills, including the ability to convey difficult and complex issues accurately and persuasively.
  • Conflict-resolution, negotiation, discussion-facilitation, and creative problem-solving skills.
  • The ability to prioritize and handle multiple projects simultaneously.
  • PC literacy and proficiency with Microsoft Office, including Outlook, Word, Excel, and PowerPoint.
  • Willingness to travel approximately 10–20%.
Responsibilities
  • Develop, implement, and advise on global regulatory strategies for development programs to secure and maintain market access in line with business objectives and internal stakeholder needs.
  • Manage regulatory aspects of compounds through all phases of development, post-approval, and product lifecycle.
  • Provide leadership and strategic regulatory oversight for designated projects, ensuring current requirements and standards are met and expedited pathways are leveraged where appropriate.
  • Advise senior management and project teams on regulatory strategy and act as a regulatory affairs and cross-functional liaison.
  • Develop global strategies for interactions with Health Authorities and interface with business partners on development, regulatory, and registration strategies.
  • Provide line management, people development, and performance management, and support or lead development and implementation of department policies.
  • Apply global regulatory knowledge strategically and operationally to development portfolios, projects, and marketed-product regulatory issues.
  • Provide strategic and operational regulatory direction and leadership on global regulatory strategies, clinical-study and marketing-approval requirements, regulatory development plans, risk assessments, critical issues, and Health Authority interactions.
  • Oversee preparation of global regulatory documentation and ensure timelines are met, including review of submission documents and amendments supporting clinical trials and marketing applications worldwide.
  • Support regional teams in negotiations with global regulatory authorities, resolve regulatory issues, and expedite product and labeling changes.
  • Assess the business and product-development impact of changes in the global regulatory environment and facilitate regulatory-policy interpretation.
  • Integrate functional expertise with business knowledge to solve problems and make decisions for the overall business.
  • Train, develop, and manage an effective regulatory team through direct and indirect reporting structures.
  • Build partnerships with stakeholders from other functions to achieve strategic business goals through knowledge and expertise sharing.
  • Manage critical issues in collaboration with regional teams and lead regulatory contributions when multiple regions are affected.
  • Assist with development and implementation of regulatory processes.
  • Recruit, develop, manage, and mentor regulatory professionals and help create a goal-oriented culture.
  • Interact with BeOne employees, senior management, external business partners, and regulatory agencies.
Desired Qualifications
  • Experience leading Regulatory Affairs across two or more major geographic areas.
  • Prior experience with both small molecules and biologics.
  • A proven track record of identifying and proactively responding to emerging regulatory trends and anticipating future strategic challenges and opportunities.
  • Experience integrating market needs and prioritization into strategy development.
  • A proven track record delivering regulatory strategies and goals in cross-functional partnerships.

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • BRUKINSA and sonrotoclax can expand fixed-duration CLL treatment standards.
  • BGB-43395 and BG-C9074 deepen breast-cancer pipeline optionality.
  • Q1 2026 revenue reached $1.5 billion, supporting broader R&D investment.

What critics are saying

  • Revenue still depends heavily on BRUKINSA, exposing the company to concentration risk.
  • Solid-tumor programs remain early-stage, with limited efficacy and tolerability data.
  • Insider stock sales can pressure sentiment despite the 10b5-1 plan.

What makes BeOne unique

  • Global oncology platform spans hematology, immunology, and solid tumors.
  • BRUKINSA anchors a leading hematology franchise across multiple approved markets.
  • Large global trial network enables faster, more cost-efficient clinical development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

-7%

1 year growth

-9%

2 year growth

-3%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...